Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
Daxor (DXR) reported significant growth in its fiscal year 2024, with its NAV increasing to $7.25 per share from $7.08 in 2023. The company's operating division achieved remarkable results, including a 116.5% revenue increase year-over-year.
Key highlights include:
- 60.1% growth in diagnostic kit sales
- 12 new customer accounts in 2024
- Achievement of cash-flow break-even in Q1 2025 (excluding non-cash expenses)
- Secured $2.5M DoD contract
- Received over $350K in NIH and Launch Tennessee grants
The company is preparing to file for FDA approval of its next-generation blood volume analyzer through the 510(k) pathway. This point-of-care system aims to enhance clinical workflows in critical care settings and expand market opportunities in both hospital and outpatient environments.
Daxor (DXR) ha riportato una crescita significativa nel suo anno fiscale 2024, con il suo NAV che è aumentato a $7.25 per azione rispetto a $7.08 nel 2023. La divisione operativa dell'azienda ha ottenuto risultati notevoli, inclusa un aumento del fatturato del 116,5% rispetto all'anno precedente.
I punti salienti includono:
- crescita del 60,1% nelle vendite di kit diagnostici
- 12 nuovi clienti acquisiti nel 2024
- Raggiungimento del pareggio di cassa nel primo trimestre del 2025 (escludendo le spese non monetarie)
- Contratto con il DoD di $2,5 milioni
- Ottenuti oltre $350K in sovvenzioni NIH e Launch Tennessee
L'azienda si sta preparando a presentare domanda per l'approvazione della FDA del suo analizzatore di volume sanguigno di nuova generazione attraverso il percorso 510(k). Questo sistema point-of-care mira a migliorare i flussi di lavoro clinici nelle situazioni di terapia intensiva e ad espandere le opportunità di mercato sia negli ospedali che negli ambienti ambulatoriali.
Daxor (DXR) reportó un crecimiento significativo en su año fiscal 2024, con su NAV aumentando a $7.25 por acción desde $7.08 en 2023. La división operativa de la empresa logró resultados notables, incluyendo un aumento del 116.5% en los ingresos en comparación con el año anterior.
Los puntos destacados incluyen:
- crecimiento del 60.1% en las ventas de kits de diagnóstico
- 12 nuevas cuentas de clientes en 2024
- Logro del punto de equilibrio de flujo de caja en el primer trimestre de 2025 (excluyendo gastos no monetarios)
- Contrato asegurado de $2.5 millones con el DoD
- Recibidos más de $350K en subvenciones de NIH y Launch Tennessee
La empresa se está preparando para presentar una solicitud de aprobación de la FDA para su analizador de volumen sanguíneo de nueva generación a través de la vía 510(k). Este sistema point-of-care tiene como objetivo mejorar los flujos de trabajo clínicos en entornos de cuidados críticos y expandir las oportunidades de mercado tanto en hospitales como en entornos ambulatorios.
Daxor (DXR)는 2024 회계연도에 상당한 성장을 보고했으며, NAV가 2023년의 $7.08에서 $7.25로 증가했습니다. 회사의 운영 부문은 전년 대비 116.5%의 수익 증가를 포함하여 주목할 만한 결과를 달성했습니다.
주요 하이라이트는 다음과 같습니다:
- 진단 키트 판매 60.1% 성장
- 2024년에 12개의 신규 고객 계정 확보
- 2025년 1분기 현금 흐름 손익 분기점 달성 (비현금 비용 제외)
- $2.5M의 DoD 계약 확보
- NIH 및 Launch Tennessee에서 $350K 이상의 보조금 수령
회사는 510(k) 경로를 통해 차세대 혈액량 분석기의 FDA 승인을 신청할 준비를 하고 있습니다. 이 포인트 오브 케어 시스템은 중환자 치료 환경에서 임상 작업 흐름을 개선하고 병원 및 외래 환경에서 시장 기회를 확장하는 것을 목표로 합니다.
Daxor (DXR) a signalé une croissance significative au cours de son exercice fiscal 2024, avec un NAV passant de $7.08 en 2023 à $7.25 par action. La division opérationnelle de l'entreprise a obtenu des résultats remarquables, y compris une augmentation des revenus de 116,5% d'une année sur l'autre.
Les points clés incluent:
- croissance de 60,1% des ventes de kits de diagnostic
- 12 nouveaux comptes clients en 2024
- Atteinte du seuil de rentabilité en termes de flux de trésorerie au premier trimestre 2025 (hors dépenses non monétaires)
- Contrat de 2,5 millions de dollars avec le DoD sécurisé
- Plus de 350K $ reçus en subventions NIH et Launch Tennessee
L'entreprise se prépare à demander l'approbation de la FDA pour son analyseur de volume sanguin de nouvelle génération via la voie 510(k). Ce système point-of-care vise à améliorer les flux de travail cliniques dans les environnements de soins critiques et à élargir les opportunités de marché dans les hôpitaux et les environnements ambulatoires.
Daxor (DXR) berichtete über ein signifikantes Wachstum im Geschäftsjahr 2024, wobei der NAV von $7.08 im Jahr 2023 auf $7.25 pro Aktie gestiegen ist. Die operative Abteilung des Unternehmens erzielte bemerkenswerte Ergebnisse, einschließlich eines Umsatzanstiegs von 116,5% im Vergleich zum Vorjahr.
Wichtige Highlights sind:
- 60,1% Wachstum bei den Verkaufszahlen von Diagnosetests
- 12 neue Kundenkonten im Jahr 2024
- Erreichung des Cash-Flow-Break-Even im 1. Quartal 2025 (ohne nicht zahlungswirksame Aufwendungen)
- Vertrag über $2,5 Millionen mit dem DoD gesichert
- Über $350K an NIH- und Launch-Tennessee-Zuschüssen erhalten
Das Unternehmen bereitet sich darauf vor, eine FDA-Zulassung für seinen Blutvolumenanalysator der nächsten Generation über den 510(k)-Weg zu beantragen. Dieses Point-of-Care-System zielt darauf ab, klinische Arbeitsabläufe in kritischen Versorgungssituationen zu verbessern und die Marktchancen sowohl in Krankenhäusern als auch in ambulanten Einrichtungen zu erweitern.
- 116.5% revenue growth in 2024
- 60.1% increase in diagnostic kit sales
- Achieved cash-flow break-even in Q1 2025
- Secured $2.5M DoD contract
- Received $350K+ in government grants
- NAV increased to $7.25 from $7.08 per share
- Record-breaking monthly kit revenue in early 2025
- Delays in new BVA system approval
Insights
Daxor's financial results represent a significant inflection point, with
The secured
The NAV increase to
The imminent FDA submission for their next-generation blood volume analyzer represents a potential catalyst that could substantially expand their addressable market. The 510(k) pathway typically offers a faster route to market than PMA alternatives, potentially bringing this point-of-care system to market in the near term.
While the CEO acknowledged approval delays, achieving cash flow positive operations from existing products demonstrates effective management execution despite these challenges, positioning the company for potentially significant growth as their product portfolio expands.
Daxor's blood volume analysis technology represents a specialized diagnostic capability with growing clinical adoption, as evidenced by their substantial increase in kit sales. The technology quantifies blood volume with precision, addressing a fundamental measurement that impacts patient care across multiple conditions including heart failure, critical care, and hypovolemic states.
The imminent 510(k) submission for their next-generation analyzer marks a important development that could significantly enhance clinical workflows. Moving from their current central lab-based system to a point-of-care platform addresses critical barriers to widespread adoption - namely, turnaround time and ease of use in time-sensitive clinical environments.
This transition to point-of-care testing potentially expands their addressable market beyond current hospital settings into outpatient environments, where volume status monitoring for chronic conditions like heart failure remains challenging. The DoD contract further validates the technology's utility in military/emergency applications where fluid management is critical.
The acceleration in kit sales (record-breaking monthly revenues in early 2025) suggests growing clinical recognition of blood volume analysis as a valuable diagnostic tool. This momentum, coupled with the pending next-generation system, positions Daxor to potentially capture significant market share in this specialized diagnostic niche as clinical evidence supporting the technology's impact on outcomes continues to develop.
Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results
Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of
The company has reported a successful 2024 and an even stronger start to 2025, driven by a series of strategic advancements in product development, revenue growth, and key acquisitions. Daxor continues to focus on transforming patient care through its innovative blood volume analysis (BVA) systems, with a mission to improve patient outcomes and reduce healthcare costs.
Key Financial and Operational Highlights From its Unaudited Operating Division:
- Revenue Growth: Daxor achieved a
116.5% increase in revenue for 2024 compared to 2023, reflecting robust demand for its diagnostic systems, a record for the company. - Customer Expansion: The company signed 12 new accounts in 2024, with
60.1% growth in the number of diagnostic kits sold year-over-year. - Operating Break-even: Daxor’s operating division achieved cash-flow break-even in Q1 of 2025, excluding non-cash expenses such as stock-based compensation, capex, and depreciation.
- Record Kit Sales: The first two months of 2025 saw record-breaking monthly kit revenue, demonstrating accelerating adoption of Daxor’s products.
- Strategic Contracts: Daxor secured a
$2.5M two-year contract from the Department of Defense (DoD), bolstering its commercial momentum in 2024. - Government Grants: The company received over
$350 K in NIH and Launch Tennessee grants to support ongoing research and development.
Next Generation Product Launch and FDA Submission:
- Daxor announced the imminent filing for its next-generation blood volume analyzer, via the rapid 510(k) approval pathway with the FDA. This breakthrough device will enable rapid, point-of-care blood volume measurements, significantly enhancing clinical workflows, particularly in critical care settings, opening new market opportunities in both hospital and outpatient environments.
“Our strong financial performance for fiscal 2024 was driven by a combination of sold, leased, placed devices for commercial and research uses, and new lab services accounts, with a dozen new clients added,” said Michael Feldschuh, Daxor’s CEO and President. “While the approval of our new BVA system has taken longer than anticipated, we still achieved our target of cash flow positive operations from the increase of our existing products. We will build on this tremendous momentum during 2025 as we get set to launch our newest point-of-care system when cleared by the FDA.”
Management has released more details from its operating division in a shareholder letter and intends to host a conference call to further discuss its results.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What was Daxor's (DXR) revenue growth percentage in 2024?
How many new accounts did Daxor (DXR) secure in 2024?
What is the value of Daxor's (DXR) Department of Defense contract secured in 2024?
What was Daxor's (DXR) NAV per share as of December 31, 2024?
When did Daxor (DXR) achieve cash-flow break-even in its operating division?
